- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06144606
Onderzoek naar KTE-X19 bij minimale restziekte (MRD) Positieve B-cel acute lymfoblastische leukemie (B-ALL)
Fase 2-studie van KTE-X19 bij minimale residuele ziekte (MRD) Positieve B-cel acute lymfoblastische leukemie (B-ALL)
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Connor Tate
- Telefoonnummer: 813-745-3783
- E-mail: ICETtrials@moffitt.org
Studie Locaties
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Moffitt Cancer Center
-
Onderonderzoeker:
- Rawan Faramand, MD
-
Onderonderzoeker:
- Frederick Locke, MD
-
Hoofdonderzoeker:
- Bijal D. Shah, MD
-
Onderonderzoeker:
- Leidy Isenalumhe, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Must be an adult 18 years of age or older.
- Pathologically confirmed CD19 positive B-cell acute lymphoblastic leukemia.
- Treatment and full recovery from induction chemotherapy, with following exceptions:
A. Vincristine associated grade 1 peripheral neuropathy B. Steroid/asparaginase associated diabetes and/or hypertension C. Inotuzumab/chemotherapy associated cytopenias
-
Patients must be in a complete remission with Minimal Residual Disease (MRD) following an induction regimen. MRD is defined herein as a bone marrow biopsy with fewer than 5% lymphoblasts. Complete remission implies the resolution of any extramedullary and/or Central Nervous Syndrome (CNS)-2-3/parenchymal disease.
-
Be willing and able to provide written informed consent/assent for the trial.
-
Able to adhere to the study visit schedule and other protocol requirements.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
-
Adequate renal, hepatic, pulmonary, cardiac function.
-
Adequate hematopoietic reserve.
-
Females of childbearing potential (FCBP) must have a negative serum pregnancy test at screening. A FCBP is considered when a sexually mature female:
1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months.
-
Subjects of both genders of child-bearing potential must be willing to practice birth control from the time of consent through 6 months after the completion of KTE-X19 infusion.
Exclusion Criteria:
- Diagnosis of L3 type Burkitt's lymphoma, Mixed-Lineage Leukemia (MLL) rearranged leukemia, biphenotypic leukemia, mixed phenotype acute leukemia, blast phase of chronic myeloid leukemia, or stem-cell leukemia.
- Any active infection requiring systemic therapy, including HIV, Hepatitis B, and/or Hepatitis C.
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator (including but not limited to unstable angina, pre-existing liver disease, recurrent pancreatitis, uncontrolled diabetes, hypertriglyceridemia, pulmonary hypertension, or severe Congestive Heart Failure (CHF).
- Recurrent thrombosis, or non-central venous catheter associated thrombosis within 3 months prior to enrollment.
- History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.
- History or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, any autoimmune disease with CNS involvement, posterior reversible encephalopathy syndrome (PRES), or cerebral edema.
- Active CNS/leptomeningeal leukemia.
- Severe comorbid conditions for which life expectancy would be <6 months.
- Patients with active (uncontrolled, metastatic) second malignancies are excluded.
- History of concomitant genetic syndrome associated with bone marrow failure such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome.
- Primary immunodeficiency or history of autoimmune disease (Crohns, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years.
- Corticosteroid therapy at a pharmacologic dose (> 5 mg/day of prednisone or equivalent doses of other corticosteroids) and other immunosuppressive drugs must be avoided for 7 days prior to enrollment.
- Presence of any indwelling line or drain (percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter). Ommaya reservoirs and dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter are permitted.
- Live vaccine ≤ 4 weeks prior to enrollment.
- Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 3 months after the last dose of trial treatment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Autologous CAR T-cell immunotherapy
Tecartus will be delivered at a target dose of 1x106 cells / kg. For those >100 kg, a flat dose of 1 x108 cells will be used. Tecartus will be administered on day 0, following 1 day of rest from conditioning chemotherapy. |
Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Relapse Free Survival (RFS)
Tijdsspanne: Up to 5 years
|
The primary endpoint is RFS, defined as the time from KTE-X19 infusion until clinical relapse or death from any cause. Patients proceeding to subsequent anti-cancer therapy, inclusive of allogeneic transplantation, without relapse will be censored in this analysis. Surviving patients not meeting criteria for relapse by the analysis data cutoff date will be censored at their last evaluable disease assessment date. |
Up to 5 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Molecular Response Rate
Tijdsspanne: Up to 5 years
|
Measured as converting to a complete molecular remission following CAR T-cell immunotherapy. Molecular remission is defined as having fewer than 0.0001% clonotype sequences per one million nucleated cells. |
Up to 5 years
|
|
Clinical Relapse Rate
Tijdsspanne: Up to 5 years
|
Measured as >5% lymphoblasts in the bone marrow and/or the emergence of extramedullary leukemia. |
Up to 5 years
|
|
Molecular Relapse Rate
Tijdsspanne: Up to 5 years
|
Measured as achieving complete molecular remission at day 28 and followed until 5 years from infusion or the emergence of detectable disease. Molecular remission is defined as having fewer than 0.0001% clonotype sequences per one million nucleated cells. |
Up to 5 years
|
|
Duration of Response (DOR)
Tijdsspanne: Up to 5 years
|
Measured as time from enrollment until clinical relapse or death. In the case of death without documented relapse, patients will be censored. |
Up to 5 years
|
|
Molecular Relapse Free Survival (MRFS)
Tijdsspanne: Up to 5 years
|
Measured by complete molecular remission at day 28 and followed until 5 years from infusion or the emergence of detectable disease. Molecular remission is defined as having fewer than 0.0001% clonotype sequences per one million nucleated cells. |
Up to 5 years
|
|
Overall Survival
Tijdsspanne: Up to 5 years
|
Measured as time from date of enrollment to date of death from any cause. |
Up to 5 years
|
|
Rate of Cytokine Release Syndrome (CRS)
Tijdsspanne: Up to 5 years
|
Participants rate of developing Cytokine Release Syndrome (CRS) |
Up to 5 years
|
|
Rate of Immune effector cell-associated neurotoxicity syndrome (ICANS)
Tijdsspanne: Up to 5 years
|
Participants rate of developing Immune effector cell-associated neurotoxicity syndrome (ICANS). |
Up to 5 years
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Bijal D. Shah, MD, Moffitt Cancer Center
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Ziekten van het immuunsysteem
- Infecties
- Virusziekten
- Neoplasmata per histologisch type
- Hematologische ziekten
- DNA-virusinfecties
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Lymfoom, non-Hodgkin
- Lymfoom, B-cel
- Lymfoom
- Leukemie, Lymfoïde
- Leukemie
- Epstein-Barr-virusinfecties
- Herpesviridae-infecties
- Tumorvirusinfecties
- Hemische en lymfatische ziekten
- Voorlopercel lymfoblastische leukemie-lymfoom
- Burkitt lymfoom
- Brexucabtagene Autoleucel
Andere studie-ID-nummers
- MCC-22286
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .